Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010

Jien Wei Liu, Wen Chien Ko, Cheng Hua Huang, Chun Hsing Liao, Chin Te Lu, Yin Ching Chuang, Shih Ming Tsao, Yao Shen Chen, Yung Ching Liu, Wei Yu Chen, Tsrang Neng Jang, Hsiu Chen Lin, Chih Ming Chen, Zhi Yuan Shi, Sung Ching Pan, Jia Ling Yang, Hsiang Chi Kung, Chun Eng Liu, Yu Jen Cheng, Yen Hsu ChenPo Liang Lu, Wu Sun, Lih Shinn Wang, Kwok Woon Yu, Ping Cherng Chiang, Ming Hsun Lee, Chun Ming Lee, Gwo Jong Hsu, Po Ren Hsueh

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC 90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were

Original languageEnglish
Pages (from-to)1414-1417
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number3
DOIs
Publication statusPublished - Mar 2012

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010'. Together they form a unique fingerprint.

  • Cite this

    Liu, J. W., Ko, W. C., Huang, C. H., Liao, C. H., Lu, C. T., Chuang, Y. C., Tsao, S. M., Chen, Y. S., Liu, Y. C., Chen, W. Y., Jang, T. N., Lin, H. C., Chen, C. M., Shi, Z. Y., Pan, S. C., Yang, J. L., Kung, H. C., Liu, C. E., Cheng, Y. J., ... Hsueh, P. R. (2012). Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010. Antimicrobial Agents and Chemotherapy, 56(3), 1414-1417. https://doi.org/10.1128/AAC.05879-11